Gene therapy in Parkinson's disease.

Abstract

Gene therapy in Parkinson's disease appears to be at the brink of the clinical study phase. Future gene therapy protocols will be based on a substantial amount of preclinical data regarding the use of ex vivo and in vivo genetic modifications with the help of viral or non-viral vectors. To date, the supplementation of neurotrophic factors and substitution for the dopaminergic deficit have formed the focus of trials to achieve relief in animal models of Parkinson's disease. Newer approaches include attempts to influence detrimental cell signalling pathways and to inhibit overactive basal ganglia structures. Nevertheless, current models of Parkinson's disease do not mirror all aspects of the human disease, and important issues with respect to long-term protein expression, choice of target structures and transgenes and safety remain to be solved. Here, we thoroughly review available animal data of gene transfer in models of Parkinson's disease.

• Authors: O Eberhardt, J B Schulz
• Journal: Cell and tissue research (Cell Tissue Res) Vol. 318 Issue 1 Pg. 243-60 (Oct 2004) ISSN: 0302-766X [Print] Germany
• PMID: 15322915 (Publication Type: Journal Article, Review)

Topics

• Animals
• Genetic Therapy (trends)
• Humans
• Parkinson Disease (genetics, therapy)